Cediranib Placebo

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Metastatic Colorectal CancerRenal Cell Carcinoma

Phase 2

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

CompletedNCT00423332

AstraZenecaRenal Cell Carcinoma

Start: 2007-01-31End: 2016-10-31Updated: 2017-02-02

Phase 3

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

CompletedNCT00399035

AstraZenecaMetastatic Colorectal Cancer

Start: 2006-11-30End: 2016-08-31Updated: 2016-12-28

Related Papers

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

2013-03-1614 citations

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

2012-01-2861 citations